Hong Kong Stocks in Focus: HENLIUS Surges Over 7% Afternoon as HLX43 Thymic Squamous Data and H-Antibody Lung Cancer Findings Set for Presentation

Stock News08-03

HENLIUS (02696) climbed more than 7% in afternoon trading, rising 7.64% to HK$59.9 with a turnover of HK$31.025 million.

On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled to take place from September 12 to 15 in Seoul, South Korea. HENLIUS will unveil several latest research findings from its innovative pipeline at this conference. These include Phase I study data on the PD-L1 ADC HLX43 in thymic squamous cell carcinoma, as well as seven sets of study data on the anti-PD-1 monoclonal antibody H-Antibody (汉斯状) in extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and pulmonary large cell neuroendocrine carcinoma.

Additionally, HENLIUS has received approval from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed innovative PD-L1 antibody-drug conjugate (ADC) injection HLX43, used in combination with bevacizumab, with or without chemotherapy, for the treatment of advanced/metastatic solid tumors. According to a concurrent announcement from Fosun Pharma, as of July 31, 2026, no similar combination therapy has been approved for marketing globally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188561348?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 15:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188561348","market":"nz","top_or_hot":-1,"title":"Hong Kong Stocks in Focus: HENLIUS Surges Over 7% Afternoon as HLX43 Thymic Squamous Data and H-Antibody Lung Cancer Findings Set for Presentation","media":"Stock News","content":"<p><b>HENLIUS (02696)</b> climbed more than 7% in afternoon trading, rising 7.64% to HK$59.9 with a turnover of HK$31.025 million.<br><br>On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled to take place from September 12 to 15 in Seoul, South Korea. <b>HENLIUS</b> will unveil several latest research findings from its innovative pipeline at this conference. These include Phase I study data on the PD-L1 ADC HLX43 in thymic squamous cell carcinoma, as well as seven sets of study data on the anti-PD-1 monoclonal antibody H-Antibody (汉斯状) in extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and pulmonary large cell neuroendocrine carcinoma.<br><br>Additionally, <b>HENLIUS</b> has received approval from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed innovative PD-L1 antibody-drug conjugate (ADC) injection HLX43, used in combination with bevacizumab, with or without chemotherapy, for the treatment of advanced/metastatic solid tumors. According to a concurrent announcement from <b>Fosun Pharma</b>, as of July 31, 2026, no similar combination therapy has been approved for marketing globally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks in Focus: HENLIUS Surges Over 7% Afternoon as HLX43 Thymic Squamous Data and H-Antibody Lung Cancer Findings Set for Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks in Focus: HENLIUS Surges Over 7% Afternoon as HLX43 Thymic Squamous Data and H-Antibody Lung Cancer Findings Set for Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 15:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HENLIUS (02696)</b> climbed more than 7% in afternoon trading, rising 7.64% to HK$59.9 with a turnover of HK$31.025 million.<br><br>On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled to take place from September 12 to 15 in Seoul, South Korea. <b>HENLIUS</b> will unveil several latest research findings from its innovative pipeline at this conference. These include Phase I study data on the PD-L1 ADC HLX43 in thymic squamous cell carcinoma, as well as seven sets of study data on the anti-PD-1 monoclonal antibody H-Antibody (汉斯状) in extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and pulmonary large cell neuroendocrine carcinoma.<br><br>Additionally, <b>HENLIUS</b> has received approval from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed innovative PD-L1 antibody-drug conjugate (ADC) injection HLX43, used in combination with bevacizumab, with or without chemotherapy, for the treatment of advanced/metastatic solid tumors. According to a concurrent announcement from <b>Fosun Pharma</b>, as of July 31, 2026, no similar combination therapy has been approved for marketing globally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1188561348","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188561348","pubTimestamp":1785740444,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) climbed more than 7% in afternoon trading, rising 7.64% to HK$59.9 with a turnover of HK$31.025 million.On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","02696":"复宏汉霖","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"港股焦点：复宏汉霖午后飙升逾7%，HLX43胸腺鳞状数据和H抗体肺癌发现即将公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1,"KCAI":1,"VXUS":1},"content_text":"HENLIUS (02696) climbed more than 7% in afternoon trading, rising 7.64% to HK$59.9 with a turnover of HK$31.025 million.On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled to take place from September 12 to 15 in Seoul, South Korea. HENLIUS will unveil several latest research findings from its innovative pipeline at this conference. These include Phase I study data on the PD-L1 ADC HLX43 in thymic squamous cell carcinoma, as well as seven sets of study data on the anti-PD-1 monoclonal antibody H-Antibody (汉斯状) in extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and pulmonary large cell neuroendocrine carcinoma.Additionally, HENLIUS has received approval from the National Medical Products Administration (NMPA) for its clinical trial application of the self-developed innovative PD-L1 antibody-drug conjugate (ADC) injection HLX43, used in combination with bevacizumab, with or without chemotherapy, for the treatment of advanced/metastatic solid tumors. According to a concurrent announcement from Fosun Pharma, as of July 31, 2026, no similar combination therapy has been approved for marketing globally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188561348","isCrawlerRequest":true}